Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Evofosfamide (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms PATH
- 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
- 08 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Mar 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.